Published in Neuropsychopharmacology on January 25, 2012
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov (2012) 1.22
Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats. J Neuroendocrinol (2013) 0.88
Dysregulation of the axonal trafficking of nuclear-encoded mitochondrial mRNA alters neuronal mitochondrial activity and mouse behavior. Dev Neurobiol (2013) 0.88
Intranasal oxytocin effects on social cognition: a critique. Brain Res (2013) 0.87
Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders. Neurobiol Stress (2015) 0.87
Nasal application of neuropeptide S inhibits arthritis pain-related behaviors through an action in the amygdala. Mol Pain (2014) 0.83
Long-lasting hippocampal synaptic protein loss in a mouse model of posttraumatic stress disorder. PLoS One (2012) 0.82
Neuropeptide S and BDNF gene expression in the amygdala are influenced by social decision-making under stress. Front Behav Neurosci (2014) 0.81
Identification of a role for the ventral hippocampus in neuropeptide S-elicited anxiolysis. PLoS One (2013) 0.81
Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Front Pharmacol (2014) 0.81
Persistent nociception induces anxiety-like behavior in rodents: role of endogenous neuropeptide S. Pain (2014) 0.81
Nuance and behavioral cogency: How the Visible Burrow System inspired the Stress-Alternatives Model and conceptualization of the continuum of anxiety. Physiol Behav (2015) 0.79
Intensity of anxiety is modified via complex integrative stress circuitries. Psychoneuroendocrinology (2015) 0.78
Intranasally applied neuropeptide S shifts a high-anxiety electrophysiological endophenotype in the ventral hippocampus towards a "normal"-anxiety one. PLoS One (2015) 0.78
Synthesis of fluorescent analogs of relaxin family peptides and their preliminary in vitro and in vivo characterization. Front Chem (2013) 0.77
Neuropeptide S receptor gene variation and neural correlates of cognitive emotion regulation. Soc Cogn Affect Neurosci (2015) 0.76
Anti-aggressive effects of neuropeptide S independent of anxiolysis in male rats. Front Behav Neurosci (2014) 0.76
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Stress and the brain: from adaptation to disease. Nat Rev Neurosci (2005) 9.48
Are the dorsal and ventral hippocampus functionally distinct structures? Neuron (2010) 6.74
Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci (2002) 4.70
The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron (2007) 4.19
Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron (2004) 3.61
Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry (2009) 3.24
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience (2004) 2.86
Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci (2010) 2.65
Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron (2008) 2.29
The synapsins: key actors of synapse function and plasticity. Prog Neurobiol (2010) 2.19
Neural bases for addictive properties of benzodiazepines. Nature (2010) 2.17
Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry (2006) 2.00
Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet (2001) 1.96
Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol (2007) 1.95
Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther (2005) 1.81
Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res (1995) 1.65
Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol (2004) 1.61
Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell (1995) 1.52
Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology (2006) 1.49
Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J Pharmacol Exp Ther (2008) 1.47
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) (2008) 1.41
Neuropeptides: opportunities for drug discovery. Lancet Neurol (2003) 1.41
Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci (2005) 1.40
Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev (2006) 1.30
Agonist-induced internalization of corticotropin-releasing factor receptors in noradrenergic neurons of the rat locus coeruleus. Eur J Neurosci (2006) 1.28
Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus. PLoS One (2008) 1.27
Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze. Pharmacol Biochem Behav (2007) 1.25
Behavioural analysis of four mouse strains in an anxiety test battery. Behav Brain Res (2000) 1.20
Facilitation of extinction learning for contextual fear memory by PEPA: a potentiator of AMPA receptors. J Neurosci (2007) 1.20
Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience (2008) 1.14
Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology (2009) 1.12
Neuropeptide S receptor gene -- converging evidence for a role in panic disorder. Mol Psychiatry (2010) 1.09
Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res (2009) 1.07
Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry (2009) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods (2002) 1.00
Immunohistochemical localization of the neuropeptide S receptor in the rat central nervous system. Neuroscience (2010) 0.98
Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology (2010) 0.97
Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci (2009) 0.97
Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain. J Neurochem (2010) 0.96
A hypomorphic vasopressin allele prevents anxiety-related behavior. PLoS One (2009) 0.96
Downstream target genes of the neuropeptide S-NPSR1 pathway. Hum Mol Genet (2006) 0.95
Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther (2008) 0.93
Intra-amygdala injections of neuropeptide S block fear-potentiated startle. Neurosci Lett (2010) 0.93
Tumor suppressor down-regulated in renal cell carcinoma 1 (DRR1) is a stress-induced actin bundling factor that modulates synaptic efficacy and cognition. Proc Natl Acad Sci U S A (2011) 0.92
Dysfunctions of cortical excitability in drug-naïve posttraumatic stress disorder patients. Biol Psychiatry (2009) 0.91
Attenuation of cocaine-induced conditioned locomotion is associated with altered expression of hippocampal glutamate receptors in mice lacking LPA1 receptors. Psychopharmacology (Berl) (2011) 0.90
Elucidation of signaling properties of vasopressin receptor-related receptor 1 by using the chimeric receptor approach. Proc Natl Acad Sci U S A (2004) 0.90
Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology (2010) 0.90
Nasal delivery of high molecular weight drugs. Molecules (2009) 0.89
Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J Drug Target (2002) 0.88
Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice. Neurosci Lett (2009) 0.86
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). J Med Chem (2011) 0.86
Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem (2010) 0.86
Characterization of receptors using cyanine 3-labeled neuropeptides. Peptides (1995) 0.86
CBT for pharmacotherapy non-remitters--a systematic review of a next-step strategy. J Affect Disord (2010) 0.82
Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br J Pharmacol (2009) 0.82
Intraventricular administration of neuropeptide S has reward-like effects. Eur J Pharmacol (2011) 0.81
Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm (2003) 0.81
Immunological localization of neuropeptide-degrading enzymes in the nasal mucosa. Rhinology (1994) 0.81
Intranasal administration of nerve growth factor produces antidepressant-like effects in animals. Neurochem Res (2010) 0.80
Identification of brain target neurons using a fluorescent conjugate of corticotropin-releasing factor. J Chem Neuroanat (2009) 0.78
Stress and the brain: from adaptation to disease. Nat Rev Neurosci (2005) 9.48
Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain. Nat Methods (2007) 8.32
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci (2012) 4.71
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nat Neurosci (2009) 4.53
The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron (2006) 4.12
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 3.61
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem (2004) 2.91
Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci (2003) 2.79
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood (2007) 2.46
Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet (2010) 2.46
RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell (2007) 2.34
Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res (2007) 2.21
Genome-wide association study of major recurrent depression in the U.K. population. Am J Psychiatry (2010) 2.17
Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch Gen Psychiatry (2011) 2.09
The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron (2011) 2.02
Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci (2012) 2.00
Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol (2009) 1.98
Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol (2002) 1.97
Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology (2013) 1.96
Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science (2002) 1.93
Self-help books for depression: how can practitioners and patients make the right choice? Br J Gen Pract (2005) 1.91
Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry (2009) 1.88
Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci (2008) 1.88
Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. Biol Psychiatry (2009) 1.85
Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis (2005) 1.83
Development of the brain's default mode network from wakefulness to slow wave sleep. Cereb Cortex (2011) 1.79
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci (2007) 1.70
Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell (2011) 1.67
Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep (2013) 1.67
Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science (2011) 1.64
Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry (2006) 1.62
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science (2009) 1.61
Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry (2005) 1.61
The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. Biol Psychiatry (2005) 1.57
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron (2008) 1.57
GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry (2002) 1.56
The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol (2004) 1.54
Increased stress reactivity is associated with reduced hippocampal activity and neuronal integrity along with changes in energy metabolism. Eur J Neurosci (2012) 1.54
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood (2005) 1.53
Time trends in eating disorder incidence. Br J Psychiatry (2005) 1.53
The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.52
Intracellular calcium stores regulate activity-dependent neuropeptide release from dendrites. Nature (2002) 1.52
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med (2006) 1.52
Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD. Psychopharmacology (Berl) (2010) 1.49
Poor cognitive flexibility in eating disorders: examining the evidence using the Wisconsin Card Sorting Task. PLoS One (2012) 1.49
Cigarette burns in forensic medicine. Forensic Sci Int (2007) 1.47
Significant genetic differentiation between Poland and Germany follows present-day political borders, as revealed by Y-chromosome analysis. Hum Genet (2005) 1.47
Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol (2002) 1.47
Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res (2008) 1.45
Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry (2006) 1.44
P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet (2006) 1.42
Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem (2003) 1.42
Infrared-guided laser stimulation of neurons in brain slices. Sci STKE (2002) 1.40
Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci (2005) 1.40
Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. J Clin Psychiatry (2015) 1.39
Are top journals biased against eating disorders topics? Am J Psychiatry (2003) 1.39
FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry (2011) 1.37
PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging (2013) 1.33
Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry (2011) 1.33
Molecular identification and physiological characterization of a novel monosaccharide transporter from Arabidopsis involved in vacuolar sugar transport. Plant Cell (2006) 1.31
Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem (2003) 1.28
Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle (2007) 1.27
Dreamed movement elicits activation in the sensorimotor cortex. Curr Biol (2011) 1.27
Altered processing of acoustic stimuli during sleep: reduced auditory activation and visual deactivation detected by a combined fMRI/EEG study. Neuroimage (2002) 1.26
Impaired extinction of learned fear in rats selectively bred for high anxiety--evidence of altered neuronal processing in prefrontal-amygdala pathways. Eur J Neurosci (2008) 1.26
An intrinsic vasopressin system in the olfactory bulb is involved in social recognition. Nature (2010) 1.24
Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle (2003) 1.23
Structural magnetic resonance imaging in eating disorders: a systematic review of voxel-based morphometry studies. Eur Eat Disord Rev (2011) 1.23
The health service use and cost of eating disorders. Psychol Med (2005) 1.22
Cognitive flexibility and clinical severity in eating disorders. PLoS One (2011) 1.22
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov (2012) 1.22
Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care (2011) 1.21
Increased sleep pressure reduces resting state functional connectivity. MAGMA (2010) 1.21
Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet (2006) 1.20
Long-term behavioral and neuroendocrine alterations following chronic social stress in mice: implications for stress-related disorders. Horm Behav (2007) 1.20
Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci U S A (2003) 1.20
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry (2003) 1.19
Heritability of sleep electroencephalogram. Biol Psychiatry (2008) 1.19
Essential role of the unusual DNA-binding motif of BAG-1 for inhibition of the glucocorticoid receptor. J Biol Chem (2002) 1.19
Neural correlates of dream lucidity obtained from contrasting lucid versus non-lucid REM sleep: a combined EEG/fMRI case study. Sleep (2012) 1.19
Overweight and obesity affect treatment response in major depression. Biol Psychiatry (2007) 1.18
Depletion of the neural precursor cell pool by glucocorticoids. Ann Neurol (2010) 1.17